The United Laboratories International Holdings Limited

HKSE 3933.HK

The United Laboratories International Holdings Limited Price to Sales Ratio (P/S) on January 28, 2025: 1.39

The United Laboratories International Holdings Limited Price to Sales Ratio (P/S) is 1.39 on January 28, 2025, a 63.72% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

The United Laboratories International Holdings Limited 52-week high Price to Sales Ratio (P/S) is 1.51 on January 02, 2025, which is 8.26% above the current Price to Sales Ratio (P/S).
The United Laboratories International Holdings Limited 52-week low Price to Sales Ratio (P/S) is 0.81 on January 30, 2024, which is -41.89% below the current Price to Sales Ratio (P/S).
The United Laboratories International Holdings Limited average Price to Sales Ratio (P/S) for the last 52 weeks is 1.15.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

HKSE: 3933.HK

The United Laboratories International Holdings Limited

CEO	Mr. Hoi Shan Tsoi
IPO Date	June 15, 2007
Location	Hong Kong
Headquarters	6 Fuk Wang Street
Employees	15,000
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies Eyewear Non-Alcoholic Beverages Personal Care Plastics

Description

The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, nervous system drugs, vitamins, and vacant gelatin capsules, as well as API and intermediate products. It also manufactures and sells soft capsules casings; holds trademarks; and trades in pharmaceutical products. In addition, the company provides management services. It has operations in the People's Republic of China, Europe, India, the Middle East, South America, other Asian regions, and internationally. The company was founded in 1990 and is headquartered in Yuen Long, Hong Kong.

Key trends

Past 5 years